Treatment of metastatic or recurrent gastric cancer with weekly 24-hour infusion of cisplatin and high-dose 5-fluorouracil/leucovorin in an outpatient setting

Tso Fu Wang, Chi Cheng Li, Sung Chao Chu, Chao Yuan Yao, Ruey Ho Kao

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Objective: There is no general agreement over a standard chemotherapy regimen for metastatic or recurrent gastric cancer. We evaluated, retrospectively, the activity and toxicity of weekly 24-hour infusion of cisplatin with high-dose 5-fluorouracil/leucovorin (P-HDFL) in an outpatient setting. Materials and Methods: Patients with metastatic or recurrent gastric cancer, treated in an outpatient setting from May 2001 to July 2005, were analyzed retrospectively. The regimen consisted of continuous infusion cisplatin 25 mg/m2, 5-fluorouracil 2000 mg/m2 and leucovorin 200 mg/m2 on day 1, 8 and 15 every 4 weeks. The treatment was continued for a maximum of six cycles unless the disease progressed or intolerable toxicities occurred. Results: Twenty-one patients received this regimen: 16 men and 5 women, median age 56 years (range 27-71). A median of 4.3 cycles was administered. Seven of 21 patients (33.3%) achieved an objective partial response. Stable disease was observed in 6 patients (28.6%) and progressive disease in 8 patients (38.1%). The median survival was 7.7 months (95% confidence interval, 6.2-12.8 months). Digestive and hematological toxicities were low and no severe renal insufficiency was observed. The most common toxicity was elevated liver enzymes (11 patients, 52%), of whom three had ≥ grade 3 toxicity: 1 of them died of hepatic failure. Conclusion: Our results show that outpatient P-HDFL therapy leads to a fairly comparable outcome with various regimens of 5-fluorouracil/cisplatin. This outpatient regimen could be a reasonable alternative that combines advantages in respect of patient activity, mild to moderate toxicity, convenience of dosing and minor expenditure.
原文英語
頁(從 - 到)432-437
頁數6
期刊Tzu Chi Medical Journal
18
發行號6
出版狀態已發佈 - 十二月 1 2006
對外發佈Yes

指紋

Leucovorin
Fluorouracil
Cisplatin
Stomach Neoplasms
Outpatients
Therapeutics
Liver Failure
Health Expenditures
Renal Insufficiency
Confidence Intervals
Drug Therapy
Survival
Liver
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Treatment of metastatic or recurrent gastric cancer with weekly 24-hour infusion of cisplatin and high-dose 5-fluorouracil/leucovorin in an outpatient setting. / Wang, Tso Fu; Li, Chi Cheng; Chu, Sung Chao; Yao, Chao Yuan; Kao, Ruey Ho.

於: Tzu Chi Medical Journal, 卷 18, 編號 6, 01.12.2006, p. 432-437.

研究成果: 雜誌貢獻文章

@article{0020ee2b778a4a5d8cb8a45f5ea6514b,
title = "Treatment of metastatic or recurrent gastric cancer with weekly 24-hour infusion of cisplatin and high-dose 5-fluorouracil/leucovorin in an outpatient setting",
abstract = "Objective: There is no general agreement over a standard chemotherapy regimen for metastatic or recurrent gastric cancer. We evaluated, retrospectively, the activity and toxicity of weekly 24-hour infusion of cisplatin with high-dose 5-fluorouracil/leucovorin (P-HDFL) in an outpatient setting. Materials and Methods: Patients with metastatic or recurrent gastric cancer, treated in an outpatient setting from May 2001 to July 2005, were analyzed retrospectively. The regimen consisted of continuous infusion cisplatin 25 mg/m2, 5-fluorouracil 2000 mg/m2 and leucovorin 200 mg/m2 on day 1, 8 and 15 every 4 weeks. The treatment was continued for a maximum of six cycles unless the disease progressed or intolerable toxicities occurred. Results: Twenty-one patients received this regimen: 16 men and 5 women, median age 56 years (range 27-71). A median of 4.3 cycles was administered. Seven of 21 patients (33.3{\%}) achieved an objective partial response. Stable disease was observed in 6 patients (28.6{\%}) and progressive disease in 8 patients (38.1{\%}). The median survival was 7.7 months (95{\%} confidence interval, 6.2-12.8 months). Digestive and hematological toxicities were low and no severe renal insufficiency was observed. The most common toxicity was elevated liver enzymes (11 patients, 52{\%}), of whom three had ≥ grade 3 toxicity: 1 of them died of hepatic failure. Conclusion: Our results show that outpatient P-HDFL therapy leads to a fairly comparable outcome with various regimens of 5-fluorouracil/cisplatin. This outpatient regimen could be a reasonable alternative that combines advantages in respect of patient activity, mild to moderate toxicity, convenience of dosing and minor expenditure.",
keywords = "5-fluorouracil, Chemotherapy, Cisplatin, Gastric cancer, Outpatient setting",
author = "Wang, {Tso Fu} and Li, {Chi Cheng} and Chu, {Sung Chao} and Yao, {Chao Yuan} and Kao, {Ruey Ho}",
year = "2006",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "432--437",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "6",

}

TY - JOUR

T1 - Treatment of metastatic or recurrent gastric cancer with weekly 24-hour infusion of cisplatin and high-dose 5-fluorouracil/leucovorin in an outpatient setting

AU - Wang, Tso Fu

AU - Li, Chi Cheng

AU - Chu, Sung Chao

AU - Yao, Chao Yuan

AU - Kao, Ruey Ho

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Objective: There is no general agreement over a standard chemotherapy regimen for metastatic or recurrent gastric cancer. We evaluated, retrospectively, the activity and toxicity of weekly 24-hour infusion of cisplatin with high-dose 5-fluorouracil/leucovorin (P-HDFL) in an outpatient setting. Materials and Methods: Patients with metastatic or recurrent gastric cancer, treated in an outpatient setting from May 2001 to July 2005, were analyzed retrospectively. The regimen consisted of continuous infusion cisplatin 25 mg/m2, 5-fluorouracil 2000 mg/m2 and leucovorin 200 mg/m2 on day 1, 8 and 15 every 4 weeks. The treatment was continued for a maximum of six cycles unless the disease progressed or intolerable toxicities occurred. Results: Twenty-one patients received this regimen: 16 men and 5 women, median age 56 years (range 27-71). A median of 4.3 cycles was administered. Seven of 21 patients (33.3%) achieved an objective partial response. Stable disease was observed in 6 patients (28.6%) and progressive disease in 8 patients (38.1%). The median survival was 7.7 months (95% confidence interval, 6.2-12.8 months). Digestive and hematological toxicities were low and no severe renal insufficiency was observed. The most common toxicity was elevated liver enzymes (11 patients, 52%), of whom three had ≥ grade 3 toxicity: 1 of them died of hepatic failure. Conclusion: Our results show that outpatient P-HDFL therapy leads to a fairly comparable outcome with various regimens of 5-fluorouracil/cisplatin. This outpatient regimen could be a reasonable alternative that combines advantages in respect of patient activity, mild to moderate toxicity, convenience of dosing and minor expenditure.

AB - Objective: There is no general agreement over a standard chemotherapy regimen for metastatic or recurrent gastric cancer. We evaluated, retrospectively, the activity and toxicity of weekly 24-hour infusion of cisplatin with high-dose 5-fluorouracil/leucovorin (P-HDFL) in an outpatient setting. Materials and Methods: Patients with metastatic or recurrent gastric cancer, treated in an outpatient setting from May 2001 to July 2005, were analyzed retrospectively. The regimen consisted of continuous infusion cisplatin 25 mg/m2, 5-fluorouracil 2000 mg/m2 and leucovorin 200 mg/m2 on day 1, 8 and 15 every 4 weeks. The treatment was continued for a maximum of six cycles unless the disease progressed or intolerable toxicities occurred. Results: Twenty-one patients received this regimen: 16 men and 5 women, median age 56 years (range 27-71). A median of 4.3 cycles was administered. Seven of 21 patients (33.3%) achieved an objective partial response. Stable disease was observed in 6 patients (28.6%) and progressive disease in 8 patients (38.1%). The median survival was 7.7 months (95% confidence interval, 6.2-12.8 months). Digestive and hematological toxicities were low and no severe renal insufficiency was observed. The most common toxicity was elevated liver enzymes (11 patients, 52%), of whom three had ≥ grade 3 toxicity: 1 of them died of hepatic failure. Conclusion: Our results show that outpatient P-HDFL therapy leads to a fairly comparable outcome with various regimens of 5-fluorouracil/cisplatin. This outpatient regimen could be a reasonable alternative that combines advantages in respect of patient activity, mild to moderate toxicity, convenience of dosing and minor expenditure.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Cisplatin

KW - Gastric cancer

KW - Outpatient setting

UR - http://www.scopus.com/inward/record.url?scp=33846138944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846138944&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33846138944

VL - 18

SP - 432

EP - 437

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 6

ER -